Amarin | AMRN - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
AbbVie USD 5.57B 2.9B 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amarin USD -852K 7.26M 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
DBV Technologies USD -33.16M 8.6M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -93M 135M 2026-03
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 3.84B 802M 2026-03